PT  - JOURNAL ARTICLE
AU  - Talal Alzahrani
AU  - Abdulelah Nuqali
AU  - Nejat Naser
AU  - Amar R Jariwala
TI  - Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease
AID  - 10.1136/bcr-2018-225680
DP  - 2019 Feb 01
TA  - BMJ Case Reports
PG  - bcr-2018-225680
VI  - 12
IP  - 2
4099  - http://casereports.bmj.com/content/12/2/bcr-2018-225680.short
4100  - http://casereports.bmj.com/content/12/2/bcr-2018-225680.full
SO  - BMJ Case Reports2019 Feb 01; 12
AB  - We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.